Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Sorafenib

Tubulin Modulators

Antimitotic Agents

Protein Kinase Inhibitors

Enzyme Inhibitors

125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.

Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)

400 mg orally twice a day continuously (even during rest week) starting on Day 1.

Sorafenib (Nexavar)

Barry Mirtsching, MD

This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer.

Each cycle will be 4 weeks in length. Patients will receive Abraxane weekly for 3 weeks. Patients will not receive Abraxane during week 4 (rest week). Nexavar will be given continuously.

Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

Bayer

Celgene Corporation

Veeda Oncology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer	NCT00607438	Breast Cancer	Paclitaxel Albu... Sorafenib (Nexa...	18 Years -	Veeda Oncology
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer	NCT00607438	Breast Cancer	Paclitaxel Albu... Sorafenib (Nexa...	18 Years -	Veeda Oncology
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer	NCT00607438	Breast Cancer	Paclitaxel Albu... Sorafenib (Nexa...	18 Years -	Veeda Oncology

Spots Global Cancer Trial Database for paclitaxel albumin nanoparticle for injectable suspension (abraxane)